US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
US9724404B2
(en)
|
2009-04-13 |
2017-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
HPV particles and uses thereof
|
EP2281579A1
(en)
*
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
CN101623503B
(zh)
*
|
2009-08-06 |
2011-07-27 |
中国人民解放军第三军医大学 |
生存素与路易斯寡糖的复合物及其制备方法和应用
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
EP2449113B8
(en)
|
2010-07-30 |
2015-11-25 |
CureVac AG |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
HUE058896T2
(hu)
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
AU2012291101B2
(en)
|
2011-07-29 |
2016-04-07 |
Riken |
Cell for use in immunotherapy which contains modified nucleic acid construct encoding Wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
|
US10316332B2
(en)
|
2011-07-29 |
2019-06-11 |
Riken |
Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RS62993B1
(sr)
|
2011-10-03 |
2022-03-31 |
Modernatx Inc |
Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
SG10201607962RA
(en)
|
2012-03-27 |
2016-11-29 |
Curevac Ag |
Artificial nucleic acid molecules
|
MX358706B
(es)
|
2012-03-27 |
2018-08-31 |
Curevac Ag |
Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
|
DK3578659T3
(da)
|
2012-03-27 |
2024-02-05 |
CureVac SE |
Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
EP4074834A1
(en)
|
2012-11-26 |
2022-10-19 |
ModernaTX, Inc. |
Terminally modified rna
|
CA2841016A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Wt1 peptide cancer vaccine composition for transdermal administration
|
RU2697443C2
(ru)
*
|
2013-02-05 |
2019-08-14 |
Нитто Денко Корпорейшн |
Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
|
CA2900975A1
(en)
|
2013-02-12 |
2014-08-21 |
Texas Tech University System |
Composition and method for diagnosis and immunotherapy of lung cancer
|
BR122021025267B1
(pt)
|
2013-02-22 |
2023-12-05 |
Curevac Ag |
Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1
|
BR112015018989B1
(pt)
*
|
2013-02-22 |
2023-11-14 |
Curevac Ag |
Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP2971165A4
(en)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
|
MX369469B
(es)
|
2013-08-21 |
2019-11-08 |
Curevac Ag |
Vacuna contra el virus respiratorio sincitial.
|
SG11201510747RA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
SG11201510751YA
(en)
*
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Composition and vaccine for treating prostate cancer
|
EP3574916A1
(en)
|
2013-08-21 |
2019-12-04 |
CureVac AG |
Composition and vaccine for treating lung cancer
|
BR112016001192A2
(pt)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
Vacina contra a raiva
|
WO2015024666A1
(en)
*
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Composition and vaccine for treating lung cancer
|
CA2915730A1
(en)
|
2013-08-21 |
2015-02-26 |
Karl-Josef Kallen |
A combination rsv/influenza a vaccine
|
WO2015042325A1
(en)
|
2013-09-18 |
2015-03-26 |
Aura Biosciences, Inc. |
Virus-like particle conjugates for diagnosis and treatment of tumors
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
MX2016004249A
(es)
|
2013-10-03 |
2016-11-08 |
Moderna Therapeutics Inc |
Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
|
CA2925021A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Ag |
Modified rna with decreased immunostimulatory properties
|
KR102399799B1
(ko)
|
2013-12-30 |
2022-05-18 |
큐어백 아게 |
인공 핵산 분자
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
JP6584414B2
(ja)
|
2013-12-30 |
2019-10-02 |
キュアバック アーゲー |
人工核酸分子
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
PT3134131T
(pt)
|
2014-04-23 |
2022-03-24 |
Modernatx Inc |
Vacinas de ácidos nucleicos
|
BR112016026980B1
(pt)
|
2014-06-10 |
2022-05-03 |
Curevac Real Estate Gmbh |
Método para sintetizar uma molécula de rna de uma dada sequência
|
WO2016077125A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
EP3218508A4
(en)
*
|
2014-11-10 |
2018-04-18 |
Modernatx, Inc. |
Multiparametric nucleic acid optimization
|
ES2791152T3
(es)
|
2014-12-12 |
2020-11-03 |
Curevac Ag |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
EP4353257A2
(en)
|
2015-04-13 |
2024-04-17 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
WO2016165831A1
(en)
|
2015-04-17 |
2016-10-20 |
Curevac Ag |
Lyophilization of rna
|
US10293058B2
(en)
|
2015-04-22 |
2019-05-21 |
Curevac Ag |
RNA containing composition for treatment of tumor diseases
|
WO2016172219A1
(en)
*
|
2015-04-24 |
2016-10-27 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation
|
SG11201708867UA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Immobilized poly(n)polymerase
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
CN107530448A
(zh)
|
2015-05-20 |
2018-01-02 |
库瑞瓦格股份公司 |
包含长链rna的干粉组合物
|
EP3916091A3
(en)
|
2015-05-20 |
2022-03-30 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
US11608513B2
(en)
|
2015-05-29 |
2023-03-21 |
CureVac SE |
Method for adding cap structures to RNA using immobilized enzymes
|
CN107873055B
(zh)
|
2015-05-29 |
2021-09-17 |
库瑞瓦格房地产有限公司 |
包括至少一个切向流过滤步骤的产生和纯化rna的方法
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
TW201718638A
(zh)
|
2015-07-21 |
2017-06-01 |
現代治療公司 |
傳染病疫苗
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
EP3362576A1
(en)
|
2015-10-12 |
2018-08-22 |
CureVac AG |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
US20190218546A1
(en)
|
2015-10-16 |
2019-07-18 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
US11413346B2
(en)
|
2015-11-09 |
2022-08-16 |
Curevac Ag |
Rotavirus vaccines
|
EP3701963A1
(en)
|
2015-12-22 |
2020-09-02 |
CureVac AG |
Method for producing rna molecule compositions
|
WO2017109161A1
(en)
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
EP3416683A1
(en)
|
2016-02-17 |
2018-12-26 |
CureVac AG |
Zika virus vaccine
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
EP3448427A1
(en)
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
EP3452493A1
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Nucleic acid molecules and uses thereof
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
CA3024744A1
(en)
*
|
2016-05-17 |
2017-11-23 |
Genecentric Therapeutics, Inc. |
Methods for subtyping of lung squamous cell carcinoma
|
US20190194760A1
(en)
|
2016-05-25 |
2019-06-27 |
Curevac Ag |
Novel biomarkers
|
KR20190029576A
(ko)
|
2016-06-09 |
2019-03-20 |
큐어백 아게 |
핵산 카고용 하이브리드 담체
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
ES2928475T3
(es)
|
2016-09-14 |
2022-11-18 |
Modernatx Inc |
Composiciones de ARN de alta pureza y métodos para su preparación
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
EP3808380A1
(en)
|
2016-12-08 |
2021-04-21 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
EP3558354A1
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Lassa virus vaccine
|
CA3051252A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
MA47515A
(fr)
|
2017-02-16 |
2019-12-25 |
Modernatx Inc |
Compositions immunogènes très puissantes
|
KR20190124750A
(ko)
|
2017-02-28 |
2019-11-05 |
사노피 |
치료적 rna
|
WO2018167320A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
BR112019015244A2
(pt)
|
2017-03-24 |
2020-04-14 |
Curevac Ag |
ácidos nucleicos codificando proteínas associadas a crispr e usos dos mesmos
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US10034951B1
(en)
|
2017-06-21 |
2018-07-31 |
New England Biolabs, Inc. |
Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
|
KR20200024905A
(ko)
|
2017-07-04 |
2020-03-09 |
큐어백 아게 |
신규 핵산 분자
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
US11524033B2
(en)
|
2017-09-05 |
2022-12-13 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
KR20200071081A
(ko)
|
2017-10-19 |
2020-06-18 |
큐어백 아게 |
신규 인공 핵산 분자
|
WO2019092153A1
(en)
|
2017-11-08 |
2019-05-16 |
Curevac Ag |
Rna sequence adaptation
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
WO2019122371A1
(en)
|
2017-12-21 |
2019-06-27 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
WO2020067453A1
(ja)
*
|
2018-09-28 |
2020-04-02 |
大日本住友製薬株式会社 |
注射用組成物
|
WO2020072914A1
(en)
|
2018-10-04 |
2020-04-09 |
New England Biolabs, Inc. |
Methods and compositions for increasing capping efficiency of transcribed rna
|
US11072808B2
(en)
|
2018-10-04 |
2021-07-27 |
New England Biolabs, Inc. |
Methods and compositions for increasing capping efficiency of transcribed RNA
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
RU2696872C1
(ru)
*
|
2019-04-11 |
2019-08-07 |
Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук" (Томский НИМЦ) |
Способ прогнозирования неблагоприятного исхода при немелкоклеточном раке легкого
|
CN112402596B
(zh)
*
|
2019-08-22 |
2023-12-08 |
上海细胞治疗集团有限公司 |
多肽组合物及疫苗
|
CN110456079B
(zh)
*
|
2019-09-20 |
2020-06-02 |
四川大学华西医院 |
Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
CN111471635B
(zh)
*
|
2020-04-13 |
2022-02-15 |
江南大学 |
一种提高枯草芽孢杆菌核酸含量的方法
|
CN116096702A
(zh)
|
2020-07-16 |
2023-05-09 |
爱康泰生治疗公司 |
用于脂质纳米颗粒的阳离子脂质
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
CN113444730A
(zh)
*
|
2021-03-17 |
2021-09-28 |
昆明市延安医院 |
一种原发性肝细胞klotho基因转导干细胞筛选构建方法
|
KR20230053998A
(ko)
|
2021-10-15 |
2023-04-24 |
(주)지노믹트리 |
mRNA 발현을 위한 유전자 구조체
|
WO2024097894A1
(en)
*
|
2022-11-04 |
2024-05-10 |
RNAimmune, Inc. |
Compositions and methods of ribonucleic acid vaccines encoding nye-so-1
|
CN115998851A
(zh)
*
|
2022-12-28 |
2023-04-25 |
四川康德赛医疗科技有限公司 |
一种个体化mRNA组合物、载体、mRNA疫苗及其应用
|